CASA antigen

01/15/1993 - "The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays."
09/01/2005 - "Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma."
07/01/1997 - "The expression of the tumor marker CASA (cancer associated serum antigen) was studied in patients with mammary carcinoma; increased values were almost exclusively seen in cases of manifest metastasis. "

03/01/2003 - "Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study."
07/01/1999 - "Due to its low specificity and the fact that some ovarian malignancies do not produce considerable amounts of CA 125 a combination with the Cancer Associated Serum Antigen (CASA) may reflect more accurately the clinical situation. "
08/01/2002 - "Significantly elevated serum levels of the tumor markers CA 15-3 and CASA (cancer-associated serum antigen) were detected, but no evidence of an underlying malignancy (including breast and ovarian) was found on serial clinical and radiologic examinations. "
06/01/1998 - "Cancer antigen 125 (CA 125) and cancer-associated serum antigen (CASA) were measured in 24 women with pelvic masses before and after a gynaecological examination and ultrasonography. "
06/01/1998 - "Can manipulation of a pelvic tumour influence the serum level of cancer antigen 125 and cancer-associated serum antigen?"

01/01/1995 - "The assays of Cancer Associated Serum Antigen (CASA) and CA 125 were assessed in the management of patients with ovarian cancer. "
05/01/1995 - "Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer."
03/15/1994 - "The Cancer associated serum antigen (CASA) and CA125 assays used in the management of ovarian cancer measure distinct high molecular weight glycoproteins. "
11/01/1995 - "Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer."

09/01/2005 - "The aim was to examine the value of the pretherapeutic serum cancer-associated serum antigen (CASA) level as a prognostic factor for survival in patients with recurrent epithelial ovarian carcinoma. "
11/01/1995 - "CA 125 and cancer-associated serum antigen (CASA) were measured prior to second-look laparotomy (SLL) to investigate their predictive and prognostic values in 93 patients treated for epithelial ovarian cancer FIGO stage II, III, or IV. Residual tumor was diagnosed at the SLL in 58 patients (62%). "
01/15/1993 - "The new tumor-associated mucin assay, cancer-associated serum antigen (CASA), was assessed with the CA 125 assay for use in the management of patients with epithelial ovarian cancer. "
09/01/1997 - "To investigate the prognostic significance of elevated levels of cancer antigen 125 (CA125), placental alkaline phosphatase (PLAP), free beta human chorionic gonadotrophin (hCG) and cancer-associated serum antigen (CASA) in women with primary epithelial ovarian carcinoma. "
09/01/1997 - "Serum concentrations of cancer antigen 125, placental alkaline phosphatase, cancer-associated serum antigen and free beta human chorionic gonadotrophin as prognostic markers for epithelial ovarian cancer."

01/01/1998 - "We have examined the predictive value of measurements of CASA (Cancer Associated Serum Antigen) levels in patients with breast carcinoma. "
01/01/1998 - "Cancer associated serum antigen (CASA) levels in patients with breast carcinoma and in 3 control groups without breast cancer."
09/15/1993 - "The tumor markers CASA (cancer-associated serum antigen) and MSA (mammary serum antigen) have previously been shown to be useful in the clinical management of ovarian and breast carcinoma, respectively, but have not been assessed in other types of cancer. "